ABPRO Holdings Inc
NASDAQ:ABP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Elec-Tech International Co Ltd
SZSE:002005
|
CN |
|
Aarvee Denims and Exports Ltd
NSE:AARVEEDEN
|
IN |
|
P
|
PJBumi Bhd
KLSE:PJBUMI
|
MY |
|
H
|
Hexing Electrical Co Ltd
SSE:603556
|
CN |
|
Net Pacific Financial Holdings Ltd
SGX:5QY
|
SG |
|
Zhejiang Starry Pharmaceutical Co Ltd
SSE:603520
|
CN |
|
Jiashili Group Ltd
HKEX:1285
|
CN |
|
T
|
Theriva Biologics Inc
AMEX:TOVX
|
US |
|
Xiaomi Corp
HKEX:1810
|
CN |
|
Meggitt PLC
LSE:MGGT
|
UK |
|
B
|
Bajaj Housing Finance Ltd
NSE:BAJAJHFL
|
IN |
|
Raymond James Financial Inc
NYSE:RJF
|
US |
|
S
|
Sino Biopharmaceutical Ltd
OTC:SBHMY
|
HK |
|
R
|
Rumere Co Ltd
SZSE:301088
|
CN |
ABPRO Holdings Inc
EPS (Diluted)
ABPRO Holdings Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ABPRO Holdings Inc
NASDAQ:ABP
|
EPS (Diluted)
-$22
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alumis Inc
NASDAQ:ALMS
|
EPS (Diluted)
-$2
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Grail Inc
NASDAQ:GRAL
|
EPS (Diluted)
-$11
|
CAGR 3-Years
62%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Oruka Therapeutics Inc
NASDAQ:ORKA
|
EPS (Diluted)
-$2
|
CAGR 3-Years
35%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
23%
|
|
|
M
|
Metsera Inc
NASDAQ:MTSR
|
EPS (Diluted)
-$2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sionna Therapeutics Inc
NASDAQ:SION
|
EPS (Diluted)
-$1
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ABPRO Holdings Inc
Glance View
ABPRO Holdings Inc is a US-based company operating in industry. The company is headquartered in New York City, New York. The company went IPO on 2022-01-14. Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The firm is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.
See Also
What is ABPRO Holdings Inc's EPS (Diluted)?
EPS (Diluted)
-22.3
USD
Based on the financial report for Dec 31, 2024, ABPRO Holdings Inc's EPS (Diluted) amounts to -22.3 USD.
What is ABPRO Holdings Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
-221%
Over the last year, the EPS (Diluted) growth was -221%.
